Jefferies Upgrades Abivax to Buy, Raises Price Target After Obefazimod Safety Improvement
ABVX•Jefferies elevated its rating of Abivax to Buy and increased its price target, citing eased safety concerns around lead immunology candidate obefazimod. The stock gained 1.7% in Paris trading as investors reacted to the improved risk profile.
1. Analyst Upgrade Details
Jefferies raised its recommendation on Abivax to Buy and lifted its price target, reflecting analysts’ growing confidence in the company’s lead immunology candidate obefazimod.
2. Safety Data Eases Concerns
Recent trial safety updates showed a reduction in serious adverse events for obefazimod, improving its risk profile and prompting the upgrade by Jefferies.
3. Market Reaction
Abivax shares jumped 1.7% in Paris trading following the upgrade, signaling investor optimism around the reduced safety risks for the immunology drug.
